Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tositumomab and iodine I 131 tositumomab
- Development stage
- Phase 3
- Lead developer
- GSK
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Tositumomab and iodine I 131 tositumomab (Bexxar) is a radioimmunotherapy regimen consisting of a murine IgG2a monoclonal antibody (tositumomab) and its iodine-131 radiolabeled counterpart. It targets the CD20 antigen expressed on the surface of B-lymphocytes. The mechanism of action involves a dual approach: the antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis induction by the tositumomab antibody, combined with targeted delivery of ionizing radiation from the iodine-131 isotope, which induces DNA damage in both targeted and neighboring 'bystander' cells. Developed by GSK, it was evaluated by the SWOG Cancer Research Network in the Phase II S0433 trial as a consolidation therapy following R-CHOP chemotherapy for patients with previously untreated advanced-stage diffuse large B-cell lymphoma (DLBCL). Commercial production and availability in the United States were discontinued by GSK in 2014.
- Other names
- I-131 tositumomabI131 tositumomabI 131 tositumomabIodine-131 tositumomabIodine131 tositumomabIodine 131 tositumomabIodine-131-Labeled Monoclonal Anti-B1 AntibodyIodine131-Labeled Monoclonal Anti-B1 AntibodyIodine 131-Labeled Monoclonal Anti-B1 Antibodytositumomab + iodine I 131 tositumomab
02
Targets
Beyond the preview
Go deeper on tositumomab and iodine I 131 tositumomab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tositumomab and iodine I 131 tositumomab.